Anthrax
Bacillus anthracis
stain of anthrax

Anthrax is an acute infectious disease of animals that can be secondarily transmitted to humans. It is caused by a bacterium ( Bacillus anthracis ) that primarily affects sheep, horses, hogs, cattle, and goats and is almost always fatal in animals. The bacillus produces toxins that kill cells and cause fluid to accumulate in the body's tissues. Anthrax spores, which can survive for decades, are found in the soil, and animals typically contract the disease while grazing. Transmission to humans normally occurs through contact with infected animals but can also occur through eating meat from an infected animal or breathing air laden with the spores of the bacilli. The disease is almost entirely occupational, i.e., restricted to individuals who handle hides of animals (e.g., farmers, butchers, and veterinarians) or sort wool.

Trifold Brochure 07 May 13
What You Need to Know About Anthrax Vaccine
Includes AVIP key messages, current policy, the threat, the disease and the vaccine, dosage schedule and route of administration, exemptions and adverse reactions.
Includes AVIP key messages, current policy, the threat, the disease and the vaccine, dosage schedule and route of administration, exemptions, adverse reactions, storage and handling of the vaccine, and documentation.
ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP) UPDATE
BUMED PDF 07 Jul 10
SUSPENSION OF REGISTRATION AND MONTHLY REPORTING REQUIREMENT FOR THE ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP)
ALARACT PDF 04 May 10
SUSPENSION OF THE ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP) REGISTRY AND MONTHLY REPORTING REQUIREMENTS
BUMED PDF 05 Nov 09
CLINICAL POLICY FOR THE ADMINISTRATION OF THE ANTHRAX VACCINE ADSORBED (AVA) UPDATE
ALMAJCOM/SG PDF 14 Jan 09
CHANGE IN ADMINISTRATION ROUTE AND DOSING SCHEDULE FOR THE ANTHRAX VACCINE ADSORBED (AVA)
ALCOAST PDF 05 Jan 09
ANTHRAX VACCINE - CHANGE IN ROUTE OF ADMINISTRATION AND IN DOSING SCHEDULE
BUMED PDF 23 Dec 08
ANTHRAX VACCINE CHANGE ROUTE OF ADMINISTRATION AND CHANGE IN DOSING SCHEDULE
27 Aug 09

Sample Q&A: Production Issues

What did the GAO say about squalene testing and what are DoD researchers doing?
In March 1999, the U.S. General Accounting Office (GAO, now the Government Accountability Office) released a report "Gulf War Illnesses: Questions about the Presence of Squalene Antibodies in Veterans Can be Resolved" (GAO/NSIAD-99-5). The Department of Defense disagreed with the GAO’s opinion that "the first step is to determine the extent to which they [antibodies to squalene] are present in a larger group of sick Gulf War-era veterans." The proper first step is to show that the test for squalene antibodies measures what it claims to measure.

Further, the medical significance and the origin of antibodies to squalene, even if their existence is corroborated, remain unknown. Without such information, Gulf War veterans get only speculation about the meaning of the test result and its implication for their health. Gulf War veterans deserve objective evidence and recommendations based on sound science. To investigate the anti-squalene antibody theory, a scientifically proven test for squalene antibodies is needed to assess whether Gulf War veterans have antibodies to squalene. In response to a DoD solicitation for research on illnesses among Gulf War veterans, a DoD investigator and nationally recognized expert on antibodies to cholesterol and other lipids submitted a research proposal to determine the feasibility of developing a test for antibodies to squalene. The competitively funded research project to determine whether antibodies to squalene exist has five main objectives:
1) Development and validation of an enzyme-linked immunosorbant assay (ELISA) for antibodies against squalene.
2) Evaluation and potential development of other assays for antibodies to squalene.
3) Development of a positive control antibody to squalene.
4) Production of the positive control antibody to squalene for use in the assays.
5) Testing of normal human serum for antibodies to squalene by ELISA and other methods.
Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
Did You Receive the Anthrax Vaccine While Pregnant?
Safety Review PDF 01 Jan 12
Detailed Safety Review of Anthrax Vaccine Adsorbed
Vaccine Healthcare Centers Network
For specialized immunization consultation and care.
VAERS 09 Jan 06
Vaccine Adverse Event Reporting System
What You Need to Know About Anthrax Vaccine
Did You Receive the Anthrax Vaccine While Pregnant?
Safety Review PDF 01 Jan 12
Detailed Safety Review of Anthrax Vaccine Adsorbed
For specialized immunization consultation and care.
Anthrax Basics 29 Jan 04
Morbidity and Mortality Weekly Report
January 24, 2003/Vol. 52/No. SS--1
Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS)
United States, 1991--2001
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Supplemental Form for Anthrax Vaccine in Pregnancy Registry
VAERS 09 Jan 06
Vaccine Adverse Event Reporting System
Anthrax Vaccine
MEDCOM form #700-R has been rescinded and is no longer to be used for recording anthrax vaccinations.
Please continue to record all vaccinations in the following places:
- Health Record Immunization Record - SF 601
- International Certification of Vaccination - PHS Form 731
- Adult Preventive and Chronic Care Flow-sheet - DD Form 2766 & DD Form 2766C
- Service automated immunization tracking system - MEDPROS/AFCITA/SAMS
FAV111 PDF 17 Mar 05
FAV114 PDF 17 Mar 05
FAV113 PDF 22 Feb 05
FAV112 PDF 15 Feb 05
FAV109 PDF 30 Dec 04
FAV110 PDF 30 Dec 04
FAV107 PDF 27 Dec 04
Package Insert - Vaccine
Department of Health and Human Services
Anthrax Vaccine Information
BioThrax
For specialized immunization consultation and care.
Anthrax eTool - Protecting the Worksite against Anthrax
VAERS 09 Jan 06
Vaccine Adverse Event Reporting System
MMQC-12-1518 27 Aug 12
RECEIPT OF THE NEW ANTHRAX TRIFOLDS
MMQC-12-1379 18 Jun 12
ANTHRAX VACCINE EXPIRATION NOTIFICATION FOR FAV304
MMQC-12-1376 15 Jun 12
ANTHRAX VACCINE EXPIRATION NOTIFICATION FOR FAV297
MMQC-12-1345 04 Jun 12
ANTHRAX VACCINE TWO WEEK NOTIFICATION FOR LOT FAV304
MMQC-12-1341 01 Jun 12
ANTHRAX VACCINE TWO WEEK NOTIFICATION FOR LOT FAV297
MMQC-12-1311 18 May 12
ANTHRAX VACCINE EXPIRATION 30-DAY NOTICE LOT FAV304
MMQC-12-1308 16 May 12
ANTHRAX VACCINE EXPIRATION 30-DAY NOTICE LOT FAV297
What You Need to Know About Anthrax Vaccine
Did You Receive the Anthrax Vaccine While Pregnant?
Safety Review PDF 01 Jan 12
Detailed Safety Review of Anthrax Vaccine Adsorbed
Vaccine Healthcare Centers Network
Vaccine Information Statement
Includes AVIP key messages, current policy, the threat, the disease and the vaccine, dosage schedule and route of administration, exemptions, adverse reactions, storage and handling of the vaccine, and documentation.
Includes AVIP key messages, current policy, the threat, the disease and the vaccine, dosage schedule and route of administration, exemptions and adverse reactions.
Safety Review PDF 01 Jan 12
Detailed Safety Review of Anthrax Vaccine Adsorbed
Vaccine Information Statement
AVIP responds with the facts about the Anthrax Vaccine
Anthrax Vaccine Immunization Program Information
Information About the Anthrax Vaccine and the Anthrax Vaccine Immunization Program (AVIP)
Questions and Answers About Anthrax
Anthrax Vaccine Package Insert Change
FAV183 PDF 04 Apr 07
FAV188 PDF 13 Mar 07
FAV186 PDF 01 Mar 07
FAV181 PDF 22 Feb 07
FAV182 PDF 22 Feb 07
FAV184 PDF 07 Feb 07
VIS
Vaccine Information Statement
Author(s): Grunow R, Klee SR, Beyer W, George M, Grunow D, Barduhn A, Klar S, Jacob D, Elschner M, Sandven P, Kjerulf A, Jensen JS, Cai W, Zimmermann R, Schaad
Publication: Eurosurveillance
Subject: Disease
Disease: 
Anthrax
Author(s): Food & Drug Administration
Publication: Federal Register 2005;70,242:75180
Subject: Vaccine-General
Disease: 
Anthrax
Author(s): ACIP
Publication: MMWR, vol. 59, no. RR-6
Subject: Vaccine-General
Disease: 
Anthrax
Author(s): BioPort Corporation
Publication: Package insert, Anthrax Vaccine Adsorbed (BioThrax) 31 Jan 2002
Subject: Vaccine-General
Disease: 
Anthrax